If decision-makers do not understand obesity to be a long-term chronic disease, thats when we see these exclusionary policies or these very, very cumbersome utilization management practices that really just set up one barrier after another to prevent people from getting the care that they need
APRs range widely, about 6.2% to 36%, and terms can go as long as seven years
RO ANNOUNCES RESEARCH COLLABORATION TO BETTER UNDERSTAND AND IMPROVE THE REAL-WORLD PATIENT EXPERIENCE WITH GLP-1S Ro's and Amgen's research will focus on barriers to care and improving access to treatment NEW YORK, Jan
has been funded by Novo Nordisk previously to create RCGP educational material and to do teaching for Novo Nordisks in house staff and is a founder of all about obesity, which has received seed funding from Novo Nordisk
Mukherjee, A., Hum, A., Gustafson, T
As with all things in biotech, the future is profoundly uncertain, and progress will always have roadblocks